###### Significance of this study

What is already known about this subject?
=========================================

-   Based on prevalence data, South Asians in the USA are a high-risk population for type 2 diabetes mellitus.

What are the new findings?
==========================

-   In this longitudinal study of immigrant South Asians in the USA, after a mean 5 years of follow-up, approximately one-third of participants had some form of glycemic conversion.

-   After adjusting for age and sex, ectopic fat depots and hypertension were strongly associated with glycemic progression.

-   After adjusting for relevant covariates, insulin secretion was associated with regression from prediabetes to normal glucose tolerance.

How might these results change the focus of research or clinical practice?
==========================================================================

-   Prevention efforts to reduce diabetes and prediabetes incidence in South Asian Americans should focus on efforts targeting ectopic fat reduction and improvements in beta-cell function and preservation through diet and physical activity interventions.

Introduction {#s1}
============

Individuals of South Asian ancestry (from Bangladesh, Bhutan, India, Pakistan, Nepal and Sri Lanka) are a rapidly growing segment of the US population. Between the years 2000 and 2010, the South Asian population in he USA increased by 68% and currently totals nearly 5.4 million.[@R1] Based on prevalence data, South Asians in the USA are a high-risk population for type 2 diabetes mellitus (T2DM),[@R2] but remain under-represented in clinical research and prospective studies.[@R6] It is unknown if South Asians experience a relatively rapid rate of transition through the natural history of T2DM development, and if they have high rates of incident prediabetes and diabetes. A recent population-based study from urban South India assessed the incidence rates of diabetes and the rates of conversion through differing stages of dysglycemia over a 10-year period.[@R7] Results of this study noted a high incidence rate of prediabetes and T2DM in this population coupled with rapid conversion from normal glycemia to prediabetes and from prediabetes to T2DM.[@R7] However, there is a lack of information on whether the incidence of prediabetes and T2DM, and the rates of conversion are similarly high in South Asians in the USA. If so, this would point to innate susceptibilities in South Asians for rapid hyperglycemic conversion above and beyond factors associated with the environment. We therefore assessed the incidence of various categories of dysglycemia including isolated impaired fasting glucose (iIFG), isolated impaired glucose tolerance (iIGT), combined impaired fasting glucose and impaired glucose tolerance (IFG+IGT) and T2DM as well as the correlates of glycemic progression in a cohort of 644 South Asian individuals in the USA who completed an oral glucose tolerance test at both baseline and follow-up.

Research design and methods {#s2}
===========================

The design, sampling strategy, recruitment, enrollment and examination components of the Mediators of Atherosclerosis in South Asians Living in America (MASALA) study have been previously described in detail.[@R8] In brief, MASALA is a community-based prospective cohort of South Asian Americans recruited from the greater San Francisco and Chicago areas. The MASALA study was designed to be similar to the Multi-Ethnic Study of Atherosclerosis (MESA),[@R9] therefore only individuals who were aged 40--84 years and had no previously known history of cardiovascular disease were eligible. In addition, participants had to self-report South Asian ethnicity (defined as having three or more grandparents born in either India, Pakistan, Nepal Bangladesh or Sri Lanka) and be able to speak and read English, Hindi or Urdu. Baseline recruitment occurred between October 2010 and March 2013. All participants were screened by telephone and then invited to either the Northwestern University or the University of California, San Francisco field center for a baseline clinical examination.[@R8]

Baseline questionnaires were completed with the assistance of bilingual study staff. Diet was assessed using the Study of Health Assessment and Risk in Ethnic Groups food frequency questionnaire, which was developed for and validated in South Asians to account for the distinct dietary intake of this population.[@R8] Mean caloric intake was calculated as the sum of the product of the frequency of consumption, nutrient composition and portion size of each item across all foods.[@R10]

Blood pressure was measured after a 5 min seated rest and was assessed with and automated blood pressure machine (V100 Vital Signs Monitor, GE Healthcare). Three measures of seated blood pressure were taken and the average of the last two readings were used to determine systolic and diastolic blood pressure. Participant height was measured using a stadiometer while weight was measured using a standing balance beam or digital scale. Body mass index (BMI) was calculated as weight in kilograms divided by height in square meters. Waist circumference was assessed using a flexible tape measure at the site of maximum circumference, halfway between the lower ribs and the anterior superior iliac spine. Waist circumference was measured twice and the average of the two measures was used in the analysis.

After a 12-hour overnight fast, a 75 g oral glucose tolerance test was administered to participants without previously diagnosed diabetes who were willing and able to participate in the glucose challenge. Blood samples were obtained from a peripheral vein just before glucose ingestion as well as 30 min and at 120 min postchallenge for plasma glucose measurements which were measured using the hexokinase method. Serum insulin was measured by the sandwich immunoassay method (Roche Elecsys 2010; Roche Diagnostics). Total cholesterol, high-density lipoprotein cholesterol and triglyceride levels were analyzed using enzymatic methods. Low-density lipoprotein cholesterol concentrations were calculated. The Millipore Luminex adipokine panel A (EMD Millipore) was used to measure adiponectin and resistin.[@R11]

CT scans of the abdomen (Philips Medical Systems; Toshiba Medical Systems; Siemens Medical Solution) were used to assess abdominal visceral, subcutaneous and intermuscular fat area. Non-contrast cardiac CT images using a cardiac-gated CT scanner (Phillips 16D scanner or Toshiba MSD Aquillion 64 at the University of California San Francisco and Siemens Sensation Cardiac 64 at Northwestern University) to assess pericardial fat volume and hepatic fat attenuation.[@R12] Specifically, intrahepatic fat was measured by quantifying radiographical hepatic fat attenuation (or density of tissue relative to surrounding tissues), with lower attenuation indicating more liver fat.[@R12]

After approximately 5 years, participants were invited back for a follow-up visit. Identical protocols for the physical examination, questionnaire and laboratory measures were conducted at baseline and follow-up, aside from 30 min glucose, which was only measured at baseline.

Glycemic status was defined according to American Diabetes Association criteria.[@R13] Diabetes was defined as previous physician diagnosis, the use of glucose-lowering medications or fasting plasma glucose ≥7.0 mmol/L or a 2-hour postchallenge glucose ≥11.1 mmol/L. Prediabetes was defined as fasting plasma glucose between 5.6 and 6.9 mmol/L and normal 2-hour postchallenge glucose (iIFG); or a 2-hour postchallenge glucose between 7.8 and 11.0 mmol/L with normal fasting plasma glucose (iIGT); or fasting plasma glucose between 5.6 and 6.9 mg/dL and 2-hour postchallenge glucose between 7.8 and 11·0 mmol/L (IFG+IGT). Normal glycemia was defined as fasting glucose \<5.6 mmol/L and 2-hour post challenge glucose \<7.8 mmol/L.

β-Cell function was estimated by the oral disposition index (DI~o~) and was calculated as (ΔI~0--30~/ΔG~0--30~)×(1/fasting insulin)[@R14] as well homeostasis model assessment (HOMA) of β-cell function was which was calculated as (20×I~0~ (µIU/mL)/G~0~ (mmol/L)−3.5).[@R15] Insulin sensitivity was estimated using the Matsuda insulin sensitivity index (ISI~M~) calculated as 10 000/√(fasting glucose×fasting insulin)×(mean oral glucose tolerance test (OGTT) glucose concentration×mean OGTT insulin concentration).[@R16] HOMA-insulin resistance (IR) was calculated as (I~0~ (µIU/mL)×G~0~ (mmol/L)/22.5).[@R15]

A total of 906 participants were enrolled in the MASALA study at baseline, and 157 individuals did not return for the follow-up visit. Of the 749 individuals at visit 2, we excluded 105 participants who did not complete an oral glucose tolerance test at either baseline or follow-up. We also excluded an additional 163 individuals with prevalent T2DM at baseline. We therefore analyzed the remaining 481 participants for incident glycemic conversion.

Statistical analysis {#s3}
====================

Study participants were characterized by glycemic status at baseline and follow-up. Baseline characteristics were described as means, geometric means and percentages by glycemic conversion status. Differences in these characteristics across glycemic conversion were assessed using χ^2^ test or analysis of variance as appropriate.

Person-years were calculated as the sum of years each person at risk contributed to the study between baseline and follow-up. Incidence rates were calculated as the number of new cases divided by person-years at risk of each glycemic conversion.

Person-year estimates for the incidence of diabetes or prediabetes were calculated from the baseline examination until the first occurrence of event incidence or last examination. Incidence of diabetes or prediabetes with 95% CIs were be calculated per 1000 person-years with the number of individuals who developed the event as the numerator and total person time as the denominator. Multivariable adjusted longitudinal regression models were used to assess the associations between risk factors and progression to diabetes or prediabetes. All analyses were performed using SAS V.9.3 (SAS Institute, Cary, North Carolina, USA).

Results {#s4}
=======

Overall, after a mean 5 years of follow-up, 152 individuals (31.6%) had any glycemic progression, either from normal glucose tolerance (NGT) to prediabetes or diabetes, or from prediabetes to T2DM ([table 1](#T1){ref-type="table"}).

###### 

Incidence rates of dysglycemia at follow up, MASALA study

  Glucose tolerance status at baseline   N                                                   Person-years      Glucose tolerance status at follow-up   Number of outcomes   Rate per 1000 person-years   95% CI
  -------------------------------------- --------------------------------------------------- ----------------- --------------------------------------- -------------------- ---------------------------- ---------------
  NGT                                    268                                                 1266              iIGT                                    25                   19.7                         13.1 to 28.7
  1266                                   iIFG                                                55                43.4                                    33.0 to 56.1                                      
  1266                                   IFG+IGT                                             29                22.9                                    15.6 to 32.5                                      
  1266                                   Any prediabetes                                     109               86.1                                    71.0 to 103.4                                     
  1266                                   T2DM                                                6                 4.7                                     1.9 to 9.9                                        
  1266                                   Any glycemic progression (to prediabetes or T2DM)   115               90.8                                    75.3 to 108.6                                     
  iIFG                                   81                                                  377               T2DM                                    7                    18.5                         8.1 to 36.7
                                         377                                                 NGT               10                                      26.5                 13.4 to 47.2                 
  iIGT                                   89                                                  423               T2DM                                    17                   40.2                         24.2 to 63.1
                                         423                                                 NGT               24                                      56.8                 37.3 to 83.3                 
  IFG+IGT                                44                                                  205               T2DM                                    13                   63.5                         35.3 to 105.9
                                         205                                                 NGT               6                                       29.3                 11.9 to 60.9                 
  Any prediabetes                        244                                                 1004              T2DM                                    37                   36.8                         26.3 to 50.2
                                         1004                                                NGT               40                                      39.8                 28.9 to 53.7                 
  NGT or any prediabetes                 482                                                 2271              T2DM                                    43                   18.9                         13.9 to 25.3
  NGT or any prediabetes                 482                                                 2271              Any glycemic progression                152                  66.9                         56.9 to 78.2
  T2DM                                   163                                                 779               NGT                                     1                    1.3                          0.1 to 6.3
                                         779                                                 Any prediabetes   9                                       11.6                 5.6 to 21.2                  

iIFG, isolated impaired fasting glucose; iIGT, isolated impaired glucose tolerance; MASALA, Mediators of Atherosclerosis in South Asians Living in America; NGT, normal glucose tolerance; T2DM, type 2 diabetes mellitus.

The incidence rate from NGT to any prediabetes was 86.1 (95% CI: 71.0 to 103.4) per 1000 person-years. The incidence rate from NGT to iIFG, 43.4 (95% CI: 33.0 to 56.1) per 1000 person-years, was higher than that to iIGT, 19.7 (95% CI: 13.1 to 28.7) per 1000 person-years. Those with iIFG had a lower rate of conversion to T2DM, 18.5 (95% CI: 8.1 to 36.7) than those with iIGT, 42.6 (95% CI: 26.0 to 66.0) or combined IFG+IGT, 63.5 (95% CI: (35.3 to 105.9). The overall incidence rate to T2DM from either NGT or prediabetes was 18.9 (13.9 to 25.3) per 1000 person-years.

In examining rates of regression from prediabetes to NGT or from T2DM to prediabetes, we found an incidence rate of regression from prediabetes to NGT of 39.8 (95% CI: 28.9 to 53.7) per 1000 person-years. The incidence rate of regression was higher from IGT to NGT (56.8 (95% CI: 37.3 to 83.3)) per 1000 person-years compared with IFG to NGT (26.5 (95% CI: 13.4 to 47.2)) per 1000 person-years or IFG+IGT to NGT (29.3 (95% CI: 11.9 to 60.9)) per 1000 person-years. Incidence rates of regression from T2DM to prediabetes or NGT were lower than those from prediabetes to NGT.

Among those with NGT at baseline, those who converted to prediabetes had a higher mean waist circumference, fasting glucose, fasting insulin, pericardial fat volume, HOMA-IR and lower ISI~M~ compared with those who remained normal glycemia ([online supplementary table 1](#SP1){ref-type="supplementary-material"}). Mean DI was lowest in those who converted to iIGT or IFG+IGT. Subcutaneous fat area was higher in those who converted to iIGT, while visceral fat area was higher in those who converted to iIFG, IFG+IGT or T2DM. Hepatic fat attenuation was lowest (suggesting higher fat content in the liver) in those who converted to iIGT.
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Among those with prediabetes at baseline, compared with those who regressed to NGT, visceral fat area, pericardial fat volume, triglycerides and the prevalence of hypertension were higher in all those who converted to T2DM. Those who converted to T2DM also had the highest mean levels of 2-hour postchallenge glucose, fasting insulin, HOMA-IR and a lower DI and ISI~M~ then those who regressed to NGT. Hepatic fat attenuation was lower in those who converted to T2DM from iIGT or IFG+IGT but not in those who converted from iIFG compared with those who regressed to NGT.

Factors that were significantly different at p≤0.05 between those who had a glycemic conversion and those who did not were included in multivariable logistic regression models. Backwards stepwise elimination was used to remove variables with a p\>0.05 from the model to retain only the most relevant covariates along with age, sex and duration of follow-up ([table 2](#T2){ref-type="table"}).

###### 

Factors related to any incident glycemic progression (A), any progression from NGT (B) and progression from prediabetes to diabetes (C) and any regression from predibetes to NGT (D) between baseline and follow-up, MASALA study

  Full model                  OR (95% CI)           OR (95% CI)
  --------------------------- --------------------- ---------------------
  Age                         1.05 (0.81 to 1.35)   1.05 (0.85 to 1.30)
  Sex                         1.96 (1.10 to 3.50)   1.26 (0.82 to 1.94)
  Follow-up time              1.30 (0.98 to 1.71)   1.27 (0.99 to 1.64)
  Hypertension                2.18 (1.34 to 3.54)   2.21 (1.44 to 3.40)
  Waist circumference         1.34 (0.85 to 2.10)   --
  BMI                         0.89 (0.80 to 0.99)   --
  Visceral fat                1.33 (0.92 to 1.92)   1.36 (1.06 to 1.74)
  Hepatic fat                 0.69 (0.52 to 0.91)   0.67 (0.55 to 0.87)
  Pericardial fat             1.08 (0.78 to 1.50)   --
  HDL                         0.80 (0.60 to 1.07)   --
  Triglycerides               1.00 (0.79 to 1.26)   --
  Disposition index           0.94 (0.75 to 1.18)   --
  Insulin sensitivity index   0.97 (0.62 to 1.51)   --

  -----------------------------------------------------------------------------------
  B.                          Any progression from NGT\   Any progression from NGT\
                              Full model                  Reduced model
  --------------------------- --------------------------- ---------------------------
  Age                         1.53 (1.07 to 2.18)         1.38 (1.03 to 1.84)

  Sex                         1.44 (0.61 to 3.38)         0.88 (0.49 to 1.58)

  Follow-up time              1.16 (0.77 to 1.75)         1.17 (0.82 to 1.67)

  Hypertension                2.19 (1.07 to 4.48)         2.26 (1.22 to 4.19)

  Waist circumference         1.69 (0.88 to 3.21)         --

  BMI                         0.87 (0.74 to 1.03)         --

  Visceral fat                1.48 (0.85 to 2.60)         1.71 (1.21 to 2.40)

  Hepatic fat                 0.84 (0.55 to 1.29)         --

  Pericardial fat             0.91 (0.56 to 1.48)         --

  HDL                         0.92 (0.61 to 1.39)         --

  Triglycerides               1.20 (0.77 to 1.86)         --

  Disposition index           0.70 (0.44 to 1.12)         --

  Insulin sensitivity index   0.68 (0.35 to 1.29)         --
  -----------------------------------------------------------------------------------

  ---------------------------------------------------------------------------------------------------
  C.                          Any progression from prediabetes\   Any progression from prediabetes\
                              Full model                          Reduced model
  --------------------------- ----------------------------------- -----------------------------------
  Age                         0.68 (0.40 to 1.17)                 1.13 (0.77 to 1.63)

  Sex                         2.77 (0.92 to 8.32)                 0.98 (0.45 to 2.16)

  Follow-up time              1.36 (0.79 to 2.35)                 1.37 (0.87 to 2.14)

  Hypertension                2.02 (0.81 to 4.99)                 --

  Waist circumference         1.16 (0.49 to 2.75)                 --

  Visceral fat                1.44 (0.72 to 2.87)                 --

  Hepatic fat                 0.56 (0.35 to 0.92)                 0.57 (0.39 to 0.84)

  Pericardial fat             1.44 (0.78 to 2.64)                 --

  HDL                         0.85 (0.47 to 1.55)                 --

  Triglycerides               0.86 (0.53 to 1.40)                 --

  Disposition index           0.99 (0.58 to 1.70)                 --

  Insulin sensitivity index   0.92 (0.31 to 2.72)                 --
  ---------------------------------------------------------------------------------------------------

  -------------------------------------------------------------------------------------------------
  D.                          Any regression from prediabetes\   Any regression from prediabetes\
                              Full model                         Reduced model
  --------------------------- ---------------------------------- ----------------------------------
  Age                         0.96 (0.60 to 1.55)                0.87 (0.59 to 1.26)

  Sex                         0.61 (0.24 to 1.55)                1.13 (0.53 to 2.43)

  Follow-up time              0.81 (0.45 to 1.43)                0.73 (0.44 to 1.22)

  Hypertension                0.35 (0.12 to 1.05)                --

  Waist circumference         1.06 (0.57 to 1.98)                --

  Visceral fat                0.61 (0.29 to 1.30)                --

  Hepatic fat                 1.01 (0.58 to 1.74)                --

  Pericardial fat             0.76 (0.37 to 1.56)                --

  HDL                         1.53 (0.86 to 2.72)                --

  Triglycerides               0.80 (0.42 to 1.53)                --

  Disposition index           3.73 (1.22 to 11.40)               4.23 (1.57 to 11.40)

  Insulin sensitivity index   1.39 (0.52 to 3.73)                --
  -------------------------------------------------------------------------------------------------

After adjusting for age, sex and duration of follow-up, hepatic fat attenuation (OR: 0.67 (95% CI: 0.55 to 0.87)), visceral fat area (OR: 1.36 (95% CI: 1.06 to 1.74)) and hypertension (OR: 2.21 (95% CI: 1.44 to 3.40)) were associated with any glycemic progression. Hepatic fat attenuation was associated with progression from prediabetes to T2DM, while visceral fat mass was associated with progression from NGT to prediabetes or T2DM. Disposition index was associated with regression from prediabetes to NGT (OR: 4.23 (95% CI: 1.57 to 11.40)).

BMI, body mass index; HDL, high-density lipoprotein; MASALA, Mediators of Atherosclerosis in South Asians Living in America; NGT, normal glucose tolerance; T2DM, type 2 diabetes mellitus.

Discussion {#s5}
==========

In this longitudinal study of immigrant South Asians in the USA, after a mean 5 years of follow-up, approximately one-third of participants had some form of glycemic conversion, either from NGT to prediabetes or diabetes, or from prediabetes to overt T2DM. There was also a high incidence rate of regression, particularly from prediabetes to NGT. We found that after adjusting for age and sex, ectopic fat depots and hypertension were strongly associated with glycemic progression, with hepatic fat being more associated with progression from prediabetes to T2DM, and visceral fat area being more strongly associated with any progression from NGT. Furthermore, DI at baseline, which is a measure of insulin secretion was strongly associated with regression from prediabetes to NGT.

Our finding suggest that glycemic progression in South Asians is more rapid than that found in whites, but is similarly high to that found in other minority race/ethnic populations. A study assessing the incidence rate of diabetes after 4.7 years of follow-up in MESA found an overall incidence rate of 16.8 per 1000 person-years among members from four different race/ethnic groups.[@R17] When stratified by race/ethnicity, African-American and Hispanics had similarly high incidence rates of T2DM (21.6 per 1000 person-years and 21.9 per 1000 person-years, respectively), while whites and Chinese Americans had lower incidence rates (11.1 per 1000 person-years and 16.2 per 1000 person-years, respectively)[@R17] compared with 18.9 per 1000 person-years in our study of South Asians. These findings suggest a high incidence of diabetes in similarly aged race/ethnic minorities in the USA including South Asians. However, the MESA study did not include 2-hour glucose tolerance tests in its definition of diabetes, and therefore the results between the two studies may not be directly comparable. An additional study estimating the incidence of diabetes among specific subgroups of Asian Americans and Pacific Islanders in a multiethnic population in the USA with uniform access to healthcare also noted a higher incidence rate of T2DM in South Asians compared with several other race/ethnic groups.[@R18] The incidence rate reported for South Asians was 17.16 per 1000 person-years, which is lower than in the current study, and may be attributed to the use of the 2-hour glucose tolerance test included in the MASALA study compared with use of fasting glucose, hemoglobin A1c or medical diagnoses in the healthcare records in the Kaiser study. While little is known about the prevalence of diabetes in various Asian subgroups in the USA, recent data suggest considerable variation, with East Asians having the lowest prevalence at 7.2%, comparable to non-Hispanic whites, while South Asians and Southeast Asians have the highest prevalence of 15.4% and 14.1%, respectively.[@R19] The high incidence rate of T2DM in South Asians is particularly alarming given that the prevalence in this population is likely to continue to grow.

When comparing the findings of our study with that of a cohort of South Indians in Chennai, India, we noted that the T2DM incidence rate from prediabetes was lower in South Asians in the USA compared with native South Indians (36.8 compared with 64.8 per 1000 person-years), however the incidence rate of prediabetes is much higher (86.1 compared with 17.5 per 1000 person-years).[@R20] These results mirror our previous findings of a lower T2DM prevalence in US-based South Asians but a lower prediabetes prevalence compared with those living in Chennai, India,[@R21] thereby suggesting that while South Asians have a high diabetes risk both in India and the Diaspora, there may be a possible shift in the relationship between migration and diabetes risk. The relatively high educational attainment, socioeconomic status (SES) and healthcare access of South Asian immigrants in the USA and in the MASALA study cohort may be a factor in slowing the transition from prediabetes to diabetes in those in the USA compared with in South Asia. Additional studies that include South Asians with greater SES variation are needed to better identify the gene-environment and lifestyle exposures that underlie glycemic progression in this population.

The results of our study point to the association between ectopic fat and glycemic progression, particularly visceral and hepatic fat. However, there were no significant associations between central and overall obesity as measure by BMI and waist circumference with glycemic progression. While it is possible that correlations between overall and central obesity and ectopic fat dilute the association of BMI and waist circumference, we performed a sensitivity analysis and found only weak-to-moderate correlations between BMI and waist circumference and visceral fat mass, pericardial fat and hepatic fat attenuation. Therefore the associations between ectopic fat and glycemic progression are likely to be independent of overall and central obesity.

Similar results regarding the associations of ectopic fat with glycemic progression have been noted in other race/ethnic groups. A study assessing the predictors of incident diabetes in Japanese Americans found that intra-abdominal fat area was a significant predictor of diabetes incidence even after adjustment for BMI, total body fat area and subcutaneous fat area.[@R22] A later study in Japanese Americans also noted that visceral adiposity increases the risk of IGT independent of IR and insulin secretion.[@R23] Furthermore, a prospective study from Japan reported that hepatic fat was associated with incident IFG and T2DM in both men and women, and the impact of hepatic fat was stronger in those with a lower BMI.[@R24] A study from Korea also noted that fatty liver increased the risk of incident T2DM after a period of 5 years, independently of IR.[@R25] Several studies have reported increased levels of visceral and hepatic fat in South Asians despite a relatively low BMI.[@R12] Therefore, reducing ectopic fat, possibly through moderate weight loss,[@R29] may be an important target in interventions aimed at reducing the incidence of diabetes and prediabetes, particularly in Asian populations. Our study also points to the association of higher insulin secretion and regression from prediabetes to NGT. Therefore, efforts aimed at improving and/or preserving insulin secretion are important considerations in terms of slowing or reversing disease progression in this population.

Our study has several strengths in that it is the first to longitudinally examine the incidence of prediabetes and T2DM in a cohort of South Asians in the USA using objective measures of glycemia as well as several radiographic measures of body composition for the assessment of ectopic fat. A limitation of the study is that MASALA study comprised an on average high-income, high-education, middle-to-older age group of South Asians from the greater San Francisco Bay and Chicago areas, and the results may not be generalisable to South Asians in other parts of the USA who are younger and/or with lower SES. However, the high risk for diabetes in South Asians in the Diaspora has been well documented,[@R3] and our study points to a rapid rate of conversion through the natural history of diabetes in this group. An additional limitation is that study analyses were limited to those who completed an oral glucose tolerance test at both baseline and follow-up. In a sensitivity analysis, we found that at baseline, those who did not complete the follow-up visit had a significantly lower mean fasting glucose than those who did complete follow-up, however there were no significant differences in baseline 2-hour glucose between the groups. Therefore, it is possible that those who did not return for follow-up may have had differing rates of glycemic progression than those who did. Additional longitudinal studies of glycemic progression in this population are thus warranted.

In conclusion, the results of our study suggest a high incidence rate of glycemic progression in South Asian Americans. Ectopic fat is strongly associated with glycemic conversion, with hepatic fat being more strongly associated with progression from prediabetes to T2DM, and visceral fat mass being more strongly associated with any progression from NGT. Our results also indicate that insulin secretion is associated with regression from prediabetes to NGT. Therefore, prevention efforts to reduce diabetes and prediabetes incidence in South Asian Americans should focus on efforts targeting ectopic fat reduction and improving or preserving insulin secretion through diet and physical activity interventions and/or pharmaceutical interventions.
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